Early approval, or even approval, under the US Food and Drug Administration’s Real-Time Oncology Review program is not guaranteed, despite an impressive record to date of application successes.
Acceptance into the RTOR program does not guarantee or influence approval of an application and does not alter review performance goals and timelines under the Prescription Drug User Fee Act,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?